Rankings
▼
Calendar
TEVA Q4 2022 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena
TEVA
Teva Pharmaceutical Industries Limited
$37B
Q4 2022 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$3.9B
-5.3% YoY
Gross Profit
$1.8B
45.6% margin
Operating Income
-$855M
-22.0% margin
Net Income
-$1.2B
-31.4% margin
EPS (Diluted)
$-1.10
QoQ Revenue Growth
+8.0%
Cash Flow
Operating Cash Flow
$973M
Free Cash Flow
$831M
Stock-Based Comp.
$36M
Balance Sheet
Total Assets
$44.0B
Total Liabilities
$35.4B
Stockholders' Equity
$7.8B
Cash & Equivalents
$2.8B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3.9B
$4.1B
-5.3%
Gross Profit
$1.8B
$2.0B
-13.7%
Operating Income
-$855M
$78M
-1196.2%
Net Income
-$1.2B
-$159M
-667.9%
Revenue Segments
Product
$3.3B
85%
Distribution Service
$460M
12%
Product and Service, Other
$54M
1%
License
$50M
1%
Geographic Segments
North America Segment
$2.0B
55%
Europe Segment
$1.1B
31%
International Markets
$482M
13%
← FY 2022
All Quarters
Q1 2023 →